GSK732461

GSK732461 is an investigational HIV-1 vaccine candidate developed by GSK. It is a biologic vaccine designed to induce robust cell-mediated immune responses, specifically targeting CD4+ T-cell activation. The vaccine construct incorporates recombinant antigens derived from the HIV-1 gag, pol, and nef proteins. It was evaluated in early-phase clinical trials to assess safety, reactogenicity, and immunogenicity, including studies investigating the interaction between the vaccine and chloroquine administration. The development of this specific candidate was part of GSK's broader HIV vaccine research program, which focused on eliciting immune responses against conserved viral proteins to provide broad protection or therapeutic benefit. Clinical development reached Phase II, but the program appears to have been discontinued.

Other names

GSK Biologicals HIV vaccine (732461)gag/pol/nef HIV vaccine